Polyvinylpyrrolidone (PVP) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a hygroscopic, free-flowing synthetic polymer powder released against the Povidone monographs Ph. Eur. 1147 and USP-NF. The line includes PVP K12, K17, K25, K30 and K90 with nominal K-value ranges of 10.5–14.5, 16.5–18.5, 24.0–27.0, 28.0–32.0 and 85.0–95.0, respectively. A 5% w/v aqueous solution of typical K30 material has a pH of 3.0–5.0; water content is controlled to ≤ 5.0%, sulfated ash to ≤ 0.1%, and nitrogen content to 11.5–12.8%. The material is freely soluble in water, methanol and ethanol and practically insoluble in ether. Because PVP is synthetic, it does not carry the BSE/TSE risk associated with gelatin or other mammalian-derived excipients, which simplifies veterinary dossier submissions. In veterinary formulations it serves as a wet-granulation binder for tablets, a solubilising and dispersing agent for injectable solutions, a binder and diluent in capsules, a stabiliser in oral powders and granules, and a protective colloid in feed premixes and solutions. Compared with technical-grade polyvinylpyrrolidone, the veterinary API grade is distinguished by pharmacopoeial impurity control for aldehydes, peroxides, hydrazine and 2-pyrrolidone; injectable-relevant lots can be supplied with monitored bacterial endotoxin and total aerobic microbial counts.

How does Povidone K-value control binder viscosity and tablet breaking force in veterinary tablet manufacture?

In wet-granulation tablet processes, PVP K30 is typically pre-dissolved in purified water to a 5.0–10.0% w/v stock solution and added in a high-shear mixer or top-spray fluid-bed granulator. The solution viscosity of K30 remains below 20 mPa·s at 25 °C for a 10% w/v solution, allowing nozzle atomisation and uniform deposition without the tackiness encountered with K90 solutions. Dry binder levels of 2.0–5.0% w/w PVP K30 are common in veterinary tablet formulations; granules are dried to a moisture content below 2.0% w/w before compression. Tablet breaking force is determined according to USP <1217>, friability according to USP <1216>, and disintegration according to USP <701>. When relative humidity during storage exceeds 60%, the hygroscopic powder and dried granules adsorb atmospheric moisture, reducing granule flow and increasing punch sticking. Sealed containers with desiccant and pre-drying at 80 °C for 2 hours are therefore applied when the material has been exposed to moisture.

Lower-K grades such as K12 and K17 produce lower-viscosity granulating solutions and are suitable for actives that require rapid granule disintegration, whereas K25 and K30 provide higher cohesive strength. K90 is reserved for sustained-release matrix formulations or for extrusion-spheronisation, where its high solution viscosity contributes to pellet cohesion; twin-screw extruders with L/D ratios between 25:1 and 40:1 are used for such matrix systems. The choice of grade must be validated against the specific active substance, impeller tip speed in high-shear mixers, and compression force profile. Published data for optimum tip-speed limits in veterinary high-shear granulation with PVP K30 is limited; bench-scale torque rheometry and Froude-number characterisation are recommended before scale-up.

Injectable grade selection and endotoxin-controlled release for PVP K12 and K17

For injectable veterinary products, PVP K12 and K17 are preferred over K30 because lower molecular weight reduces solution viscosity and facilitates sterile filtration through 0.22 µm polyvinylidene fluoride or polyether sulfone membranes at 20–25 °C. A 5.0% w/v aqueous K12 solution yields a low-viscosity vehicle suitable for solubilising poorly water-soluble actives. The API can be dissolved in water for injection, filtered, and autoclaved at 121 °C for 15 min; however, terminal sterilisation must be confirmed because PVP can bind certain preservatives and may reduce free preservative concentration in multidose formulations. Endotoxin limits are not fixed for all grades by the povidone monograph; injectable-relevant lots are released with bacterial endotoxin and total aerobic microbial count specifications agreed with the finished-product manufacturer. When no supplier-specific limit is available, the finished injectable product limit defined by the regional pharmacopoeia or by VICH GL11 governs the acceptable API endotoxin burden.

PVP can interact with phenolic preservatives such as benzyl alcohol and parabens; free preservative concentration must be assayed after compounding because the polymer may reduce antimicrobial activity. This incompatibility is a measured operational boundary, not a general prohibition, and requires a preservative efficacy test according to Ph. Eur. 5.1.3 or USP <51> for the final multidose formulation. Solutions formulated with PVP K12 or K17 should be protected from moisture and stored in tight containers; exposure to relative humidity above 60% results in caking and increases the risk of microbial proliferation in non-sterile powders.

For veterinary capsules, dry blending of PVP K25 or K30 at 0.5–3.0% w/w provides granule binding after slugging or roller compaction without the moisture sensitivity of wet-granulated material. Capsule content uniformity is assessed according to USP <905>; dissolution of the finished capsule is measured by USP <711>. In oral powders and granules for reconstitution, PVP K90 at 1.0–5.0% w/w acts as a stabiliser and viscosity modifier, slowing sedimentation of suspended actives after reconstitution. Feed premixes containing vitamins, trace minerals or coccidiostats are stabilised with PVP K30 at low inclusion rates, where the polymer functions as a dispersion aid and particulate binder. Published data for optimum premix inclusion rates in specific veterinary species are limited; the inclusion rate should be determined by sieve analysis of the finished premix after mixing in a ribbon blender or V-blender. In all dry systems, blending time must be controlled because PVP is hygroscopic and static charge can cause segregation; an inline sieve and humidity-controlled compounding area below 60% RH reduce batch-to-batch variation.

When PVP K30 is substituted for copovidone or hypromellose in veterinary oral solutions and premix carriers

When a formulation replaces copovidone with PVP K30, the higher hygroscopicity of PVP must be addressed in packaging and drying. A 5.0% w/v aqueous PVP K30 solution has a lower solution viscosity than many copovidone grades at the same concentration, but PVP homopolymer absorbs atmospheric moisture more readily than copovidone. Compared with hypromellose, PVP provides a less pronounced gel-swell viscosity profile in oral solutions; this difference is measured by rotational viscometry at 25 °C under defined shear rates, with viscosity values reported according to ISO 3219 or USP <911>. The substitution is therefore appropriate when rapid dissolution, low solution viscosity and direct wet-granulation binding are required, but not when a thermally reversible gel or enteric release profile is needed. Packaging in aluminium-laminated foil with desiccant is used to maintain water content below 5.0% during storage in tropical climates.

Compendial release parameters are verified lot-to-lot before veterinary API shipment

Release of veterinary PVP API is controlled against the Povidone monograph and residual solvent/elemental impurity risk assessments. Residual solvent control follows VICH GL18, which mirrors ICH Q3C; elemental impurities are managed under ICH Q3D risk assessment when regional submissions require the data. The following table lists the compendial physical and chemical controls applied to the API before release.

The grade-selection table below summarises primary veterinary dosage-form assignments; the assigned grade is not a regulatory prohibition but a starting point for formulation development.